Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
- First Posted Date
- 2012-04-12
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT01576406
- Locations
- 🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇺🇸LAC&USC Medical Center, Los Angeles, California, United States
🇺🇸Keck Hospital of USC, Los Angeles, California, United States
Drug Drug Interaction Study Of Crizotinib With Esomeprazole.
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01549574
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT01531361
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01500824
A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2012-10-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01419041
- Locations
- 🇺🇸
Pfizer Investigational Site, Saint Paul, Minnesota, United States
Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT01297595
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT01168934
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Bioequivalence And Food Effect Study Comparing The Commercial Formulation Of Crizotinib To Its Clinical Study Formulations And Commercial Formulation With Or Without Food In Healthy Volunteers
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01154218
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01149785
- Locations
- 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States
Estimation Of Effect Of Rifampin On Pharmacokinetics Of Crizotinib In Healthy Volunteers
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01147055
- Locations
- 🇺🇸
Pfizer Investigational Site, South Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.